D-1006-2019 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-1006-2019 was initiated by Teva Pharmaceuticals USA on Mar 11, 2019 and is designated Class III. Reason for recall: Subpotent Drug. The recall status is terminated (terminated Nov 15, 2019). Affected quantity: 7,081 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 27, 2019
Initiation Date
Mar 11, 2019
Termination Date
Nov 15, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
7,081 bottles

Product description

Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg, 100 tablets (10 blister cards of 10 tablets each), Rx only, Manufactured in Israel By: Teva Pharmaceutical Ind. Ltd. Jerusalem, 9777402, Israel, Manufactured for: Teva Pharmaceuticals USA, Inc. North Wales, PA 19454, NDC 0093-3008-93

Reason for recall

Subpotent Drug.

Distribution pattern

Nationwide in the United States.

Code information

Lot #: 25Q002, Exp. 11/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1006-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1006-2019. Report a data issue: hello@regdatalab.com.